These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 2060543)

  • 1. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
    Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
    J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
    Heller F; Harvengt C
    Eur J Clin Pharmacol; 1983; 25(1):57-63. PubMed ID: 6617725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates and triglyceride metabolism.
    Schwandt P
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S41-3. PubMed ID: 2044642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
    Julius U; Hora C; Gross P; Fücker K; Bergmann S; Hanefeld M
    Fortschr Med; 1992 Dec; 110(35-36):669-72. PubMed ID: 1487226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
    Vázquez M; Merlos M; Adzet T; Laguna JC
    Br J Pharmacol; 1996 Mar; 117(6):1155-62. PubMed ID: 8882610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM; Vega GL
    Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
    Krause BR; Newton RS
    Atherosclerosis; 1986 Jan; 59(1):95-8. PubMed ID: 3081014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
    Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
    Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.